Perrigo

1.06%

Perrigo Company plc is a global healthcare company that develops, manufactures and distributes over-the-counter (OTC) consumer goods, prescription medicines, and nutritional products. The company was founded in 1887 in Allegan, Michigan, and has since expanded to become one of the largest OTC pharmaceutical companies in the world. Perrigo's products can be found in over 130 countries, with their primary markets in the United States, Europe, and Israel.
Perrigo's mission is to make quality healthcare more affordable and accessible for people around the world. The company prides itself on its high-quality, affordable products, and its commitment to innovation and research. Perrigo has a wide range of products, including over 5,000 OTC and prescription medications, vitamins and supplements, infant and toddler nutrition, and personal care products.
In addition to its focus on healthcare, Perrigo also places a strong emphasis on corporate social responsibility and sustainability. The company is committed to ethical business practices, reducing its environmental impact, and giving back to the communities it serves.
Perrigo has received numerous awards and recognition for its products, research, and corporate culture. This includes recognition as one of the Top 100 Most Sustainable Corporations in the World by Corporate Knights, and being named a Top Workplace by the Detroit Free Press for several consecutive years.
Overall, Perrigo is a reputable and innovative company that plays a significant role in providing affordable and accessible healthcare products to people around the world.

There are a few things that make the Perrigo company stand out:
1. Strong Commitment to Quality: Perrigo has a strict quality control process and a reputation for producing high-quality products. They have invested in advanced technology and rigorous testing processes to ensure their products meet the highest standards.
2. Affordable Healthcare Solutions: Perrigo is known for making over-the-counter medications and products, as well as generic prescription medications, more affordable for consumers. This has made them a popular choice among cost-conscious consumers and healthcare providers.
3. Global Reach: Perrigo has a global presence, with operations in over 40 countries. This allows them to serve a wide range of consumers and healthcare markets around the world.
4. Diverse Product Portfolio: Perrigo offers a diverse range of healthcare products, including over-the-counter medicines, vitamins, supplements, and generic prescription drugs. This allows them to cater to a variety of healthcare needs and reach a broad customer base.
5. Commitment to Sustainability: Perrigo is committed to reducing their environmental impact and promoting sustainability in their operations. They have implemented several initiatives, such as reducing waste and energy consumption, to achieve this goal.
Overall, Perrigo's reputation for quality, affordability, global reach, and commitment to sustainability make them a unique and reputable company in the healthcare industry.

The Perrigo Company is a leading global healthcare supplier that develops, manufactures, and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients (APIs). Their business model focuses on three key strategies: Portfolio Optimization, Operational Excellence, and Growth.
Portfolio Optimization involves continuously evaluating and improving their product portfolio to meet changing market demands and customer needs. This includes expanding their portfolio through organic growth, acquisitions, and partnerships, as well as divesting non-core assets.
Operational Excellence entails streamlining operations and supply chain processes to improve efficiency and reduce costs, thus maximizing financial performance.
Growth is achieved through entering new markets, expanding product lines, and leveraging strategic alliances and partnerships. They also invest in research and development to bring new products to market that meet the needs of their customers.
Overall, Perrigo's business model is focused on providing high-quality, affordable healthcare products to consumers worldwide while continuously seeking opportunities for innovation and growth.

1. Perrigo was founded in 1887 by Luther and Charles Perrigo in Allegan, Michigan. The company originally focused on producing patent medicines and household remedies.
2. In the early 1900s, Perrigo began manufacturing over-the-counter (OTC) medicines and quickly became a leading OTC provider in the United States.
3. In 1934, Perrigo became one of the first drug companies to offer its products in pre-measured doses, under the brand name Elixir Sulfanilamide. This innovation helped make medication dosing safer and more accurate.
4. In the 1970s, Perrigo expanded its product line to include private label products, which are manufactured for other companies and sold under their own brand names. This shift in strategy helped the company become a major player in the OTC market.
5. Perrigo was the first company to offer generic over-the-counter versions of major brand-name products, such as Wal-Born vitamin C tablets and Sudafed nasal decongestant.
6. The company’s headquarters are now located in Dublin, Ireland, but it maintains a strong presence in Allegan, Michigan, where its first factory was built.
7. In 2017, Perrigo established a $10 million endowment at Michigan State University’s College of Human Medicine to support research in neurodegenerative diseases and pharmaceutical process chemistry.
8. Perrigo is one of the leading producers of store brand OTC medications and personal care products, with its products sold in over 35 countries and territories.
9. In addition to OTC medications, Perrigo also produces a range of prescription drugs, animal health products, infant formula, and nutritional supplements.
10. In 2020, Perrigo announced plans to merge with generic drug company Mylan, which would create a company with over $30 billion in annual sales. The merger is expected to be completed in late 2020 or early 2021.